Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report) insider Jude Onyia sold 11,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $160.25, for a total value of $1,762,750.00. Following the sale, the insider directly owned 25,846 shares in the company, valued at approximately $4,141,821.50. This trade represents a 29.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jude Onyia also recently made the following trade(s):
- On Wednesday, May 27th, Jude Onyia sold 11,000 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $155.53, for a total value of $1,710,830.00.
Neurocrine Biosciences Stock Performance
NBIX opened at $154.84 on Wednesday. The firm has a market cap of $15.57 billion, a P/E ratio of 23.86, a price-to-earnings-growth ratio of 1.21 and a beta of 0.40. Neurocrine Biosciences, Inc. has a 52-week low of $122.14 and a 52-week high of $162.39. The business’s fifty day moving average is $139.98 and its 200-day moving average is $139.18.
Institutional Trading of Neurocrine Biosciences
Analyst Upgrades and Downgrades
NBIX has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $185.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, April 6th. Wolfe Research initiated coverage on Neurocrine Biosciences in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $160.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating and issued a $175.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Neurocrine Biosciences in a research note on Tuesday, April 21st. Finally, Morgan Stanley raised their price objective on Neurocrine Biosciences from $185.00 to $191.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $187.52.
Read Our Latest Stock Analysis on NBIX
Neurocrine Biosciences Company Profile
Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.
The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.
Featured Articles
- Five stocks we like better than Neurocrine Biosciences
- Marvell Stock Soars on NVIDIA’s Trillion-Dollar Nod
- FirstCash Turns Pawn Into a Growth Machine
- HubSpot Just Crushed the Bear Case—Is a Bigger Rally Ahead?
- Aggressive Insider Buying Signals Opportunity in 3 Risky Stocks
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
